Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Balance Sheets (Current Period Unaudited)

v3.21.1
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2021
Jun. 30, 2020
Current assets:    
Cash and cash equivalents $ 186,136 $ 146,625
Short-term available-for-sale investments 90,108 124,268
Accounts receivable, net of $1,428 and $775 of reserves, respectively 157,790 122,534
Inventories 109,990 103,152
Other current assets 22,582 24,341
Total current assets 566,606 520,920
Property and equipment, net 198,975 176,829
Right of use asset 71,830 71,465
Goodwill 746,460 728,308
Intangible assets, net 489,178 516,545
Other assets 11,593 13,522
Total assets 2,084,642 2,027,589
Current liabilities:    
Trade accounts payable 25,842 23,090
Salaries, wages and related accruals 43,268 31,087
Accrued expenses 15,689 9,093
Contract liabilities 18,714 13,049
Income taxes payable 3,562 2,376
Operating lease liabilities - current 10,414 9,535
Contingent consideration payable 5,070 5,938
Current portion of long-term debt obligations 12,500 12,500
Other current liabilities 2,581 0
Total current liabilities 137,640 106,668
Deferred income taxes 98,401 101,090
Long-term debt obligations 202,931 344,243
Long-term contingent consideration payable 7,100 199
Operating lease liabilities 66,816 67,248
Other long-term liabilities 23,812 26,949
Bio-Techne's shareholders' equity:    
Undesignated capital stock, no par; authorized 5,000,000 shares; none issued or outstanding 0 0
Common stock, par value $.01 per share; authorized 100,000,000; issued and outstanding 38,854,000 and 38,453,046, respectively 389 385
Additional paid-in capital 514,299 420,536
Retained earnings 1,088,788 1,057,470
Accumulated other comprehensive loss (64,023) (97,199)
Total Bio-Techne shareholders' equity 1,539,453 1,381,192
Noncontrolling interest 8,489 0
Total shareholders’ equity 1,547,942 1,381,192
Total liabilities and shareholders’ equity $ 2,084,642 $ 2,027,589